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a b s t r a c t
Parkinsonism-hyperpyrexia syndrome (PHS), or neuroleptic malignant syndrome (NMS), is a
neurophysiologic reaction to the acute withdrawal/decrease of central dopamine levels. It is
a severe complication characterized by rigidity, change in consciousness level, fever,
hypertension, and autonomic instability, that can be fatal. To the best of our knowledge,
PHS following deep brain stimulation (DBS) of subthalamic nucleus (STN) surgery due to
anti-Parkinson drug discontinuation has been previously reported only six times. Half of
these cases resulted in fatalities. Herein, we report on an early diagnosed case of PHS
following bilateral STN-DBS which was successfully treated with the administration of
dopamine agonists, ﬂuid replacement, and activation of DBS.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
is an established option for the treatment of advanced
Parkinson's disease (PD). Patients with tremor-affected quality
of life, medically uncontrollable motor ﬂuctuations, or
dyskinesia are candidates for DBS [1]. These patients usually* Corresponding author at: Liv Hospital Ulus, Ahmet Adnan Saygun A
E-mail address: moakcakaya@gmail.com (M.O. Akçakaya).
https://doi.org/10.1016/j.pjnns.2017.11.012
0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Nhave a long history of multiple, high-dose, anti-PD drug usage
[2]. Prior to DBS surgery, the anti-PD drugs are temporarily
discontinued to better observe patients' responses during
surgery in most centers [2]. There is also a common tendency
to reduce the use of anti-PD drugs postoperatively. The sudden
withdrawal of anti-PD drugs may trigger a severe, fatal
complication known as parkinsonism-hyperpyrexia syn-
drome (PHS), which is characterized by rigidity, change in
consciousness level, fever, hypertension, and autonomicve. Canan Street, no: 5, Besiktas, Istanbul, Turkey.
eurological Society.
Fig. 1 – (a) and (b) Control MRI scan showed that the position
of the depth electrode is appropriate on the right side,
however too much medially located in the left side as
shown by the axial T1 (a) and T2-weighted (b) images.
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PD drug withdrawal is routinely used in clinical practice, to
date, only six cases of PHS have been reported following STN-
DBS surgery [2–7]. Fifty percent of these cases resulted in
fatalities despite aggressive medical treatment efforts [3–5].
Herein, we report on a case of PHS which was recognized early
on, following bilateral STN-DBS, and successfully treated with
the administration of dopamine agonists, ﬂuid replacement,
and DBS activation.
2. Case report
A 61-year-old male with a 14-year history of PD was admitted
for DBS surgery. His symptoms had progressed over the years
with a predominant tremor. The Uniﬁed Parkinson Disease
Rating Scale Part III (UPDRS-III) showed an improvement of
24% on the levodopa test. Although motor response to
levodopa test is accepted as the primary selection criteria
for DBS in Parkinson disease, in our patient who do not meet
the 33% threshold, DBS was performed for medication-
refractory tremor. The patient had been taking levodopa-
benserazide, 600–150 mg/day, trihexyphenidyl 6 mg/day, and
amantadine 300 mg/day preoperatively. 12 h before the oper-
ation, medications that the patient had been taking were
withdrawn in order to observe the clinical response to the
microelectrode stimulation. On the day of surgery, following
magnetic resonance imaging (MRI) of the brain, a stereotactic
frame (Integra CRW, New Jersey, USA) was placed onto
patients head and patient underwent computed tomography
(CT) scan. Then, the MRI and CT images were auto-fused using
an image fusion program (Atlas Integra Software, New Jersey,
USA) in order to target anterolateral side of right and left STN.
Bilateral microeletrode recordings and macro stimulation
tests were performed (Alfa Omega NeuroNav Micro Recording
System, Nazareth, Israel). DBS electrodes were placed then
bilaterally to anterolateral sides of both STNs (St. Jude Medical
6149 40 cm lead, Minnesota, USA). The cranial skin incisions
were closed and the patient was brought to the radiology unit.
A control cranial MRI revealed that the left sided STN electrode
position found to be inappropriate (Fig. 1a and b). The left sided
electrode was corrected under microelectrode recording and
macro stimulation tests. Then permanent electrode position-
ing was conﬁrmed with cranial MRI (Fig. 2a–c). The stereotactic
frame was removed, the patient was intubated. Under general
anesthesia, the impulse generator (St. Jude Medical Libra XP
6644, Minnesota, USA) was implanted and connected to the
leads. The total length of this procedure was 12 h. Our protocol
dictates that every patient who undergoes DBS surgery is
routinely followed up overnight in the intensive care unit
(ICU). Starting from the sixth postoperative hour in the ICU, the
patient suffered from a high fever (up to 39 8C), confusion,
generalized tremor, elevated blood pressure, and extreme
axial rigidity. Autonomic dysfunctional attacks presented with
tachycardia, blood pressure ﬂuctuations, and diaphoresis.
Deterioration of consciousness was also encountered. Intra-
venous (IV) hydration and empiric antibiotic treatment
(vancomycin 4  500 mg and meronem 2  2000 mg) were
administered immediately to counteract a possible central
nervous system infection, although it is unusual in such an
Fig. 2 – (a)–(c) Postoperative control T1-weighted MRI (a:
axial, b: coronal, c: sagittal) confirmed the DBS final
electrode positioning in STN.
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showed no abnormalities except mild pneumocephalus and
no evidence of late onset hemorrhage. Blood tests, including
complete blood count, liver enzymes, and electrolytes, were all
within normal limits. There was a mild increase in the C-
reactive protein test which is in accordance with postoperative
values (34.31). The creatinine kinase (CK) level was elevated to
1524 U/L. A PHS diagnosis was established, and the patient's
preoperative medical treatment was restarted immediately. In
addition, bromocriptine treatment of 7.5 mg/day (3  2.5 mg)
was administered. On the second postoperative day, the
clinical picture had not changed signiﬁcantly. The CK level
continued to increase up to 2170 U/L. Under normal circum-
stances, we prefer to activate the DBS system one-week aftersurgery in order to observe reducement of the lesion effect of
the DBS lead for more precise device programming. However,
considering the mortality risk and the unchanged clinical
picture in this case, the DBS system was activated (Bipolar
stimulation, left and right STN Amplitude: 1.5 mA, pulse
width: 60 mS, frequency: 130 Hz) at the second postoperative
day, and the bromocriptine dosage was increased to 15 mg/day
(6  2.5 mg). With this treatment strategy, the CK values
decreased from the third postoperative day. At fourth
postoperative day stimulation parameters were increased to
2 mA in amplitude and to 70 in pulse width bilaterally. Tremor,
rigidity, and confusion resolved gradually, and the number of
autonomic dysfunctional attacks decreased. The CK level was
down to 340 U/L on the sixth postoperative day, and the
patient was discharged from the ICU. With four additional
days of service care, stimulation parameters were rearranged
(right and left STN Amplitude: 2.5 mA, pulse width: 70 mS,
frequency: 130 Hz) and the patient was discharged from the
hospital on the 10th postoperative day. Considering the PHS,
the patient's medication could not be decreased until three
months following the surgery. There was an improvement of
35% in UPDRS-III scores on 6th month postoperatively; the
disabling tremor, especially, was signiﬁcantly improved.
3. Discussion
PHS or acute dopamine depletion syndrome is a neurophysio-
logic reaction to the acute withdrawal/decrease of central
dopamine levels [8,9]. As well as being caused by the
withdrawal of dopaminergic (anti-parkinsonian) drugs, PHS
has also been reported due to the discontinuation of DBS.
Diagnostic criteria were proposed by Granner and Wooten in
1991, which included ‘‘primary’’ (proper pharmacologic setting
use of dopamine-receptor antagonists, or withdrawal of L-
dopa or dopamine agonists, Parkinsonism, and fever in the
absence of infection) and ‘‘secondary’’ (autonomic instability,
altered mental state, and elevated creatinine kinase) mani-
festations [8].
Early recognition and diagnosis of PHS is essential in order
to prevent morbidity and mortality. Clinical deterioration of
Parkinsonism and increased body temperature are the
primary signs of PHS. Readministration of the dopaminergic
drugs that the patient used in the past is of utmost importance.
According to the clinical picture, bromocriptine (7.5–15 mg/
day), amantadine oral/IV, or IV methylprednisolone (1 g)
should be added to the medical treatment [9]. Proper
supportive treatment (hydration, reduction of fever, respira-
tory support, etc.) and detailed ICU follow-up are essential. To
reduce rigidity, sodium dantrolene (2–3 mg/kg/day IV) may be
used. The patient should be closely monitored for renal and
hepatic functions and coagulation factors. The CK levels also
need to be closely monitored. Possible complications of PHS
may include rhabdomyolysis, acute renal failure, deep venous
thrombosis, pulmonary embolism, disseminated intravascu-
lar coagulation, aspiration pneumonia, and seizures [9].
Differential diagnoses may include infectious diseases, alco-
hol, and other drug (benzodiazepines) withdrawal states [8].
Treatment options that affect central dopamine levels,
such as electroconvulsive therapy (ECT), have been performed
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insufﬁcient [10]. It is thought that STN stimulation also
contributes to our patient with a similar mechanism as ECT.
Because it is known that STN stimulation causes negligible
amounts of dopamine release in the striatum similar to the
resting state in humans [11].
The drug withdrawal before DBS surgery was seen as the
cause of PHS in most cases. However, in each of these cases
published in the literature including the current report, there
was also a drug withdrawal for levodopa test. Although we
observed no signiﬁcant changes or deterioration during
levodopa tests, clinicians should kept in mind that they
may observe some clinical signs, which may give a clue of a
possible PHS risk.
In late onset cases of PHS unlike ours, drug reducement
regimens may play a role. Unfortunately there are no certain
guidelines or sufﬁcient studies that addresses drug based
management of PD patients following DBS. A recent review by
Fasano et al., documented that although there are many
studies focusing on the outcome of DBS, there is no study
about the drug management in the postoperative period [12].
They underlined that to date, the best way to manage motor
and non-motor symptoms in PD while balancing levodopa and
a dopamine agonist remains largely unknown and this
management was solely based on personal or institutional
preferences and experience [12]. But in general, care must be
taken by drug reducement to prevent immediate and signiﬁ-
cant reductions in levodopa and dopamine agonists.
To our knowledge, there have been only six other cases of
PHS following DBS surgery published in the literature [2–7].
Three of these six cases resulted in fatalities, despite
aggressive treatment [3–5]. DBS surgery of STN generally
reduces PD symptoms; however, it may sometimes result in an
increase of dyskinesia similar to that of a dopamine overdose
state [3]. Dyskinesia, however, is usually seen as a favorable
sign as it indicates improvement of motor symptoms in PD [3].
Urasaki et al. suggested that continuous STN stimulation may
suppress PHS and possibly result in a delay in the diagnosis [3].
On the other hand, continuous STN stimulation has been
pointed out as the cause of early recovery from PHS [2,7]. We
believe that the close monitoring of our patient in ICU was very
important in the early recognition of the disease. Once the
diagnosis had been established, STN stimulation played a
positive role by accelerating our patient's recovery. However,
one must be aware that STN stimulation may mask the clinical
features of PHS and leave the diagnosis uncertain.
We reinstituted medical therapy, and, in addition, bromo-
criptine treatment was given. The patient was followed up
according to the clinical course and CK level monitoring. We
think that the complete and quick clinical recovery in our
patient with PHS, which is known for its high mortality rate, is
related to the early recognition of the disease, early establish-
ment of appropriate medical and supportive therapy, and early
activation of the DBS system.
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